This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...

Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI ...

The advent and proliferation of targeted modalities represent an evolutionary leap forward in drug development. By binding ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in free cash flow and $10 billion profits over the training 12 months alone. So, ...

As part of the new schedule, HHS will no longer broadly recommend influenza, COVID-19, rotavirus, and other previously ...

Biologically, how the GLP-1 is delivered into the body should make little difference: It’s the same peptide, just in a ...

Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization.

The integration of flexible manufacturing, process intensification, and sustainability is redefining the global supply chain.

GovCIO is proud to mark the successful early deployment of Phase 1 of the Readiness and Employment System (RES), a major ...

This study examines the co-movement dynamics of inflation rates among Southern African Development Community (SADC) member ...

Biopharma enters 2026 amid continuing scientific progress and accelerating deal activity, yet its business model is under pressure across every facet of the value chain. Investors are taking note: ...